Masulaxavir Tablets——China's first independently developed anti-influenza drug targeting PA

On March 27, according to the official website of NMPA: Masulaxavir Tablets (trade name: Isuda), a Class 1 innovative drug applied for by Jiangxi Kerui Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical, was approved for marketing. It is used to treat previously healthy adolescents and adults aged 12 years and above with simple influenza A and B, excluding patients at high risk of influenza-related complications.
In recent years, the incidence of influenza has continued to rise internationally , driving a surge in demand for anti-influenza drugs. According to Yaozhi data, the market size of anti-influenza drugs in China will approach 20 billion yuan in 2023. In such a huge market context, the approval of Masulaxavir Tablets is undoubtedly a blockbuster.

Masulaxavir tablets are an innovative anti-influenza virus drug jointly developed by Qingfeng Pharmaceutical and Ginkgo Biloba Pharmaceuticals. It is a polymerase acidic protein (PA) inhibitor. It is worth mentioning that as China's first independently developed PA-targeted anti-influenza drug, the registered clinical data of Masulaxavir tablets are all from Chinese patients, and it has sufficient evidence-based evidence from the Chinese population, which is extremely rare among similar drugs.

Masulaxavir tablets exert their potent antiviral ability by targeting the key links of viral replication. At the same time, the drug has the high convenience of single administration and the advantage of low risk of drug resistance. These characteristics make it an important breakthrough in the field of influenza treatment. Its Chinese attributes further enhance the prospects for clinical application, and it is very likely to stand out in the influenza drug market in the future.

https://news.yaozh.com/archive/45237.html